Learn more →
Back to Expert Scholars
medical-oncology / medical-oncologyColorectal Cancer

Arnaud Roth

阿尔诺·罗斯

MD

🏢Geneva University Hospital (HUG)(日内瓦大学医院)🌐Switzerland

Head of Gastrointestinal Oncology, Medical Oncology Division消化道肿瘤科主任,医学肿瘤部

48
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Dr. Arnaud Roth is a distinguished Swiss GI oncologist and principal investigator of multiple PETACC colorectal cancer trials, defining adjuvant chemotherapy standards for colon cancer in Europe. His work on FOLFOX and capecitabine regimens has shaped colorectal cancer treatment guidelines globally.

Share:

🧪Research Fields 研究领域

Colorectal Cancer结直肠癌
GI Oncology消化道肿瘤
Adjuvant Chemotherapy辅助化疗
Clinical Trials临床试验

🎓Key Contributions 主要贡献

Adjuvant Colorectal Cancer Treatment

Led PETACC-3 and contributed to PETACC-8 trials, defining the role of irinotecan and oxaliplatin-based adjuvant chemotherapy in stage III colon cancer and helping establish FOLFOX as standard.

Biomarker Integration in Colorectal Cancer

Pioneered biomarker analyses within PETACC trials, identifying MSI status, KRAS, and other molecular markers as predictors of adjuvant chemotherapy benefit in colon cancer.

European Colorectal Cancer Collaboration

Long-standing leader within the Pan-European Trials in Adjuvant Colon Cancer (PETACC) consortium, coordinating multicenter trials across dozens of European institutions.

Representative Works 代表性著作

[1]

FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer

Journal of Clinical Oncology (2004)

Landmark European study comparing irinotecan- versus oxaliplatin-based regimens in metastatic CRC, establishing equipotency and guiding sequencing decisions.

[2]

PETACC-3: Irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin in stage II-III colon cancer

Journal of Clinical Oncology (2006)

Demonstrated no significant benefit of irinotecan addition to LV5FU2 in stage III colon cancer, refining adjuvant chemotherapy standards in Europe.

[3]

Predictive biomarkers of adjuvant chemotherapy in colon cancer: PETACC-3 biomarker study

Annals of Oncology (2014)

Identified molecular subgroups predictive of adjuvant chemotherapy response, advancing personalized treatment strategies in colon cancer.

🏆Awards & Recognition 奖项与荣誉

🏆Swiss Cancer Research Award
🏆ESMO GI Oncology Faculty Recognition
🏆PETACC Consortium Leadership Award
🏆Swiss Society of Medical Oncology (SSMO) Distinguished Investigator Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 阿尔诺·罗斯 的研究动态

Follow Arnaud Roth's research updates

留下邮箱,当我们发布与 Arnaud Roth(Geneva University Hospital (HUG))相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment